ZEVRA THERAPEUTICS, INC. (ZVRA) SEC Filings

Zevra Therapeutics’ affiliate reports planned stock sales by an insider. A Form 144 notice lists up to 42,666 shares of common stock held in an account at Morgan Stanley Smith Barney LLC Executive Financial Services for potential sale on NASDAQ as of August 14, 2026.

The shares relate to restricted stock units granted on June 21, 2025 by the issuer. The notice also references prior Rule 10b5-1 sales for Rahsaan Thompson, including 34,557 common shares sold for $438,303.71 on June 22, 2026.

Woodline Partners LP, a Delaware limited partnership and investment adviser to Woodline Master Fund LP and Woodline Spire Master Fund LP, reported its beneficial ownership of common stock of Zevra Therapeutics, Inc. on an amended Schedule 13G. Woodline Partners is deemed to beneficially own 4,785,771 shares of Zevra common stock, representing 8.1% of the class, based on 59,115,084 shares outstanding as of May 1, 2026. Woodline has sole voting and dispositive power over these shares and no shared power. Woodline Master Fund LP has the right to receive or direct the receipt of dividends and sale proceeds related to the reported shares.

Director Corey Michael Watton of Zevra Therapeutics, Inc. exercised stock options for 12,300 shares of common stock at an exercise price of $4.97 per share and on the same date sold 12,300 shares of common stock at a weighted average price of $11.2502 per share, in multiple trades ranging from $11.23 to $11.31. Following the option exercise, Watton held 46,500 stock options that remain outstanding and fully vested under the reported award.

FMR LLC reports beneficial ownership of 4,915,717 shares of ZEVRA THERAPEUTICS INC common stock, representing 8.3% of the class, on a Schedule 13G/A. FMR LLC has sole voting power over 4,899,562 shares and sole dispositive power over 4,915,717 shares, with no shared voting or dispositive power.

Abigail P. Johnson is listed with sole dispositive power over 4,915,717 shares and no voting power, reflecting her control position related to FMR LLC. One or more other persons may receive dividends or sale proceeds from these shares, but no such person has an interest exceeding five percent of the outstanding common stock.

Zevra Therapeutics, Inc. reported strong results for the six months ended June 30, 2026, with net revenue of $75.9 million and net income of $46.6 million, driven primarily by sales of MIPLYFFA and contributions from an expanded access program and AZSTARYS royalties.

MIPLYFFA generated $54.9 million and OLPRUVA $0.5 million in product sales over six months, while the global expanded access program contributed $19.1 million, net of clawback and related adjustments. A $43.3 million gain was recorded from the sale of SDX-related assets to Commave, after required sharing with Aquestive.

The balance sheet strengthened meaningfully: cash and cash equivalents rose to $145.3 million and all long-term debt of $61.9 million at December 31, 2025 was fully repaid in March 2026. Total liabilities fell to $85.1 million and stockholders’ equity increased to $217.7 million. Zevra also notes a July 2026 negative CHMP opinion on the MIPLYFFA marketing application in Europe, for which it has requested re-examination, and continues a Phase 3 trial of celiprolol in VEDS.

Zevra Therapeutics reported Q2 2026 net revenue of $39.7 million, a 53% increase over Q2 2025. Revenue included $30.2 million from MIPLYFFA, $0.2 million from OLPRUVA, $9.0 million in reimbursements from the global Expanded Access Program, and $0.3 million from AZSTARYS royalties and other reimbursements.

Cost of product revenue was $1.5 million, and operating expenses were $21.0 million, including $3.0 million of stock compensation. Net income was $8.8 million, or $0.14 per basic and diluted share. Excluding warrant and CVR fair value adjustments in Q2 2026 and significant one-time items in Q2 2025, management estimates adjusted net income of $15.2 million in Q2 2026 versus an adjusted net loss of $2.4 million in Q2 2025.

Cash, cash equivalents and investments totaled $260.2 million as of June 30, 2026, and long-term debt had been eliminated. Common shares outstanding were 59,341,906, with fully diluted shares of 69,298,10566 patients with three confirmed events, and the company plans further FDA engagement in the second half of 2026.

Vanguard Capital Management reports passive ownership of Zevra Therapeutics Inc common stock on a Schedule 13G. Vanguard and specified affiliates beneficially own 3,024,980 shares, representing 5.11% of the outstanding class. Vanguard has sole voting power over 386,070 shares and sole dispositive power over all 3,024,980 shares, with no shared voting or dispositive power reported. The position reflects securities held by Vanguard funds and managed accounts where Vanguard or its listed affiliates exercise dispositive and/or voting authority, while interests of other disaggregated Vanguard affiliates are excluded. No other single person is stated to have an interest in more than 5% of this class through Vanguard’s holdings.

Zevra Therapeutics, Inc. reported that Chief Legal & Compliance Officer Rahsaan Thompson exercised equity awards and sold shares. On June 21, 2026, he exercised 66,667 restricted stock units, receiving the same number of common shares at a stated price of $0.00 per share. After this exercise, his direct holdings were 114,792 common shares. On June 22, 2026, he completed an open-market sale of 34,557 common shares at a weighted average price of $12.6835 per share, leaving him with 80,235 common shares held directly. Footnotes explain that each restricted stock unit converts into one common share and outline a vesting schedule for the RSU grant, as well as a referenced Rule 10b5-1(c) plan adoption date.